Trials / Terminated
TerminatedNCT00434356
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, Phase II, randomized, controlled, open label trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with bevacizumab and paclitaxel in patients who have not previously received chemotherapy for locally recurrent or metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | Intravenous repeating dose |
| DRUG | sunitinib | Oral repeating dose |
| DRUG | paclitaxel | Intravenous repeating dose |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-05-01
- First posted
- 2007-02-13
- Last updated
- 2009-12-03
- Results posted
- 2009-12-03
Source: ClinicalTrials.gov record NCT00434356. Inclusion in this directory is not an endorsement.